miR‑374c‑5p regulates PTTG1 and inhibits cell growth and metastasis in hepatocellular carcinoma by regulating epithelial‑mesenchymal transition

miR-374c-5p通过调控上皮间质转化调控PTTG1抑制肝细胞癌的细胞生长和转移

阅读:9
作者:Gang Yang, Yongfu Xiog, Guan Wang, Weinan Li, Tao Tang, Ji Sun, Jingdong Li

Abstract

A large number of studies have reported that microRNA (miR)‑374c‑5p plays an important role in the occurrence and development of malignant tumors, but there is no research on the role of miR‑374c‑5p in hepatocellular carcinoma (HCC). The aim of the present study was to investigate the role of miR‑374c‑5p in HCC and the underlying molecular mechanism. The expression of miR‑374c‑5p in HCC tissues and HCC cell lines was analyzed via reverse transcription‑quantitative PCR. The association between miR‑374c‑5p and clinical pathology was also analyzed in patients with HCC. Kaplan‑Meier analysis and Cox multivariate analysis were used to evaluate the prognostic significance of miR‑374c‑5p in HCC. The biological functions of miR‑374c‑5p, including cell proliferation, migration and invasion and its potential molecular mechanism were analyzed in vivo and in vitro. In addition, the molecular mechanism of miR‑374c‑5p in HCC was further explored. The results demonstrated that miR‑374c‑5p expression was lower in HCC than in matched adjacent tissue samples. Patients with low expression of miR‑374c‑5p had poor prognosis and short survival time. Overexpression of miR‑374c‑5p inhibited HCC cell proliferation, migration and invasion in vitro. In vivo, it was found that overexpression of miR‑374c‑5p significantly inhibited the growth and proliferation of HCC cells. Dual‑luciferase reporter assays verified that miR‑374c‑5p directly targets the 3'‑untranslated region of pituitary tumor‑transforming 1 (PTTG1) and regulates PTTG1 expression. In general, it was revealed that miR‑374c‑5p regulates the malignant biological behavior of HCC through PTTG1, thereby affecting epithelial‑mesenchymal transition. Thus, miR‑374c‑5p is a potential biological indicator to predict poor prognosis in patients with HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。